SCHEDULE 13G/A: Maverick Capital Amends Stake in Verona Pharma, Disclosing 3.8% Beneficial Ownership
Beneficial Ownership Report
Maverick Capital, Ltd. and its affiliates have filed an amended Schedule 13G, disclosing a 3.8% beneficial ownership stake in Verona Pharma Plc as of December 31, 2024.
Summary
- Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III collectively reported beneficial ownership of 25,028,128 Ordinary Shares of Verona Pharma Plc.
- This ownership represents 3.8% of the total outstanding Ordinary Shares of Verona Pharma Plc.
- The shares are held through various investment vehicles, including Maverick Fund USA, Ltd., Maverick Fund II, Ltd., Maverick Long Enhanced Fund, Ltd., Maverick HP, L.P., Maverick Long Fund, Ltd., and certain separately managed accounts.
- The reported Ordinary Shares are primarily held in the form of 3,128,516 American Depositary Shares (ADSs), with each ADS representing eight Ordinary Shares.
- The ownership percentage is calculated based on 654,649,358 outstanding Ordinary Shares, as reported by Verona Pharma Plc in its Quarterly Report on Form 10-Q filed with the SEC on November 4, 2024.
- This filing is an Amendment No. 1 to Schedule 13G, indicating an update to a previously reported beneficial ownership position.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual and routine disclosure of beneficial ownership and does not contain performance, strategic updates, or forward-looking statements.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an institutional investor and does not provide specific insights into broader industry trends or competitive landscape for Verona Pharma Plc.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership stake of a significant institutional investor, Maverick Capital, Ltd., and its affiliates.
Key Dates
| Date | Description |
|---|---|
| 2018-03-15 | Date of Power of Attorney granted to Trevor Wiessmann to sign on behalf of Lee S. Ainslie III. |
| 2024-11-04 | Date Verona Pharma Plc filed its Quarterly Report on Form 10-Q, reporting 654,649,358 outstanding Ordinary Shares. |
| 2024-12-31 | Date of event which requires the filing of this statement (reporting period end date). |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Verona Pharma Plc, Maverick Capital, Schedule 13G, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.